Enanta Pharmaceuticals, Inc.
NASDAQ: ENTA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jay R. Luly
- Employees
- 131
- Headquarters
- Watertown, United States
- IPO year
- 2013
- Market cap
- $318.5M
- Website
- https://www.enanta.com
Loading ENTA…
Loading profile data…Frequently asked questions about ENTA
What does Enanta Pharmaceuticals, Inc. (ENTA) do?
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneum...
Where does ENTA trade?
Enanta Pharmaceuticals, Inc. (ENTA) trades on the NASDAQ Global Select.
What sector is ENTA in?
Enanta Pharmaceuticals, Inc. (ENTA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enanta Pharmaceuticals, Inc.?
Jay R. Luly is the chief executive officer of Enanta Pharmaceuticals, Inc. (ENTA).
Where is Enanta Pharmaceuticals, Inc. headquartered?
Enanta Pharmaceuticals, Inc. is headquartered in United States.
Does ENTA pay a dividend?
Enanta Pharmaceuticals, Inc. (ENTA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENTA go public?
Enanta Pharmaceuticals, Inc. (ENTA) completed its initial public offering in 2013.